Dolutegravir Pubchem Food

facebook share image   twitter share image   pinterest share image   E-Mail share image

More about "dolutegravir pubchem food"

DOLUTEGRAVIR | C20H19F2N3O5 - PUBCHEM
dolutegravir-c20h19f2n3o5-pubchem image
Web Dolutegravir | C20H19F2N3O5 | CID 54726191 - structure, chemical names, physical and chemical properties, classification, patents, …
From pubchem.ncbi.nlm.nih.gov
Molecular Formula C20H19F2N3O5
PubChem CID 54726191


DOLUTEGRAVIR: USES, INTERACTIONS, MECHANISM OF ACTION
dolutegravir-uses-interactions-mechanism-of-action image
Web 435 rows Aug 12, 2013 Cations can be administered with dolutegravir …
From go.drugbank.com


TIVICAY, TIVICAY PD (DOLUTEGRAVIR) DOSING, INDICATIONS, …
tivicay-tivicay-pd-dolutegravir-dosing-indications image
Web Administer dolutegravir at least 2 hr before or 6 hr after each dose to avoid chelation with magnesium. . sodium sulfate/potassium sulfate/magnesium sulfate. sodium sulfate/potassium sulfate/magnesium sulfate decreases …
From reference.medscape.com


DOLUTEGRAVIR - PATIENT | NIH - CLINICALINFO
dolutegravir-patient-nih-clinicalinfo image
Web Mar 13, 2023 Dark-colored urine. Light-colored bowel movements. Loss of appetite for several days or longer. Nausea or vomiting. Pain, aching, or tenderness on the right side of your stomach/abdominal area. Itching. …
From clinicalinfo.hiv.gov


DOLUTEGRAVIR SODIUM | C20H18F2N3NAO5 - PUBCHEM
dolutegravir-sodium-c20h18f2n3nao5-pubchem image
Web Dolutegravir sodium | C20H18F2N3NaO5 | CID 46216142 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, …
From pubchem.ncbi.nlm.nih.gov


DOLUTEGRAVIR SODIUM MONOHYDRATE | C20H20F2N3NAO6 …
dolutegravir-sodium-monohydrate-c20h20f2n3nao6 image
Web Dolutegravir sodium monohydrate | C20H20F2N3NaO6 | CID 76969888 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity …
From pubchem.ncbi.nlm.nih.gov


DOLUTEGRAVIR(1-) | C20H18F2N3O5- - PUBCHEM
dolutegravir1-c20h18f2n3o5-pubchem image
Web Dolutegravir (1-) | C20H18F2N3O5- - PubChem Apologies, we are having some trouble retrieving data from our servers... PUGVIEW FETCH ERROR: 403 Forbidden National Center for Biotechnology Information 8600 …
From pubchem.ncbi.nlm.nih.gov


DOLUTEGRAVIR - WIKIPEDIA
Dolutegravir is approved for use in a broad population of HIV-infected patients. It can be used to treat HIV-infected adults who have never taken HIV therapy (treatment-naïve) and HIV-infected adults who have previously taken HIV therapy (treatment-experienced), including those who have been treated with other integrase strand transfer inhibitors. Tivicay is also approved for children ages 12 years and older weighing at least 40 kilograms (kg) who are treatment-naïve or treatme…
From en.wikipedia.org
Formula C₂₀H₁₉F₂N₃O₅
Trade names Tivicay, Tivicay PD
Pregnancy category AU


EFFECT OF FOOD ON THE PHARMACOKINETICS OF THE INTEGRASE ... - PUBMED
Web Food increased dolutegravir exposure and reduced the rate of absorption. The area under the concentration-time curve from 0 h to infinity (AUC(0-∞)) increased by 33%, 41%, and …
From pubmed.ncbi.nlm.nih.gov
Author Ivy Song, Julie Borland, Shuguang Chen, Parul Patel, Toshihiro Wajima, Amanda Peppercorn, Stephen C....
Publish Year 2012


WHO WELCOMES FDA APPROVAL OF NEW FORMULATION OF DOLUTEGRAVIR …
Web Jun 18, 2020 WHO welcomes the recent decision by the U.S. Food and Drug Administration (FDA) to approve a dispersible 5 mg formulation of dolutegravir (DTG) …
From who.int


DOLUTEGRAVIR USES, SIDE EFFECTS & WARNINGS - DRUGS.COM
Web Jul 19, 2022 Dolutegravir is an antiviral medicine that is used with other medications to treat HIV, the virus that can cause the acquired immunodeficiency syndrome (AIDS). …
From drugs.com


NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION
Web National Center for Biotechnology Information
From ncbi.nlm.nih.gov


DOLUTEGRAVIR ORAL: USES, SIDE EFFECTS, INTERACTIONS, PICTURES
Web Dolutegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This …
From webmd.com


TIVICAY | EUROPEAN MEDICINES AGENCY
Web Mar 7, 2023 Tivicay is a medicine used together with other medicines to treat adults and children from 4 weeks of age and weighing at least 3 kg who are infected with human …
From ema.europa.eu


ENHANCED SOLUBILITY AND BIOAVAILABILITY OF DOLUTEGRAVIR BY SOLID ...
Web Apr 9, 2021 Being a candidate of BCS class II, dolutegravir (DTG), a recently approved antiretroviral drug, possesses solubility issues. The current research was aimed to …
From pubmed.ncbi.nlm.nih.gov


DOLUTEGRAVIR | AIDSMAP
Web Dolutegravir is a medication used to treat HIV, marketed under the brand name Tivicay. It is taken in combination with other antiretroviral drugs. The usual adult dose of dolutegravir …
From aidsmap.com


CLINICAL PHARMACOKINETIC, PHARMACODYNAMIC AND DRUG-INTERACTION …
Web Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing approval. The in …
From pubmed.ncbi.nlm.nih.gov


CHEMICAL STRUCTURE OF DOLUTEGRAVIR. NOTE: REPRODUCED FROM …
Web The US Food and Drug Administration (FDA) approved dolutegravir/rilpivirine (DTGR/RLVN) as the first twin antiretroviral single tablet combination regimen for the …
From researchgate.net


FOOD REQUIREMENTS FOR ANTI-HIV MEDICATIONS | AIDSMAP
Web Some HIV medications need to be taken with food. This is because food helps them to be absorbed effectively or reduces side effects such as nausea. Some people worry this will …
From aidsmap.com


DOLUTEGRAVIR | DEFINITION OF DOLUTEGRAVIR BY MEDICAL DICTIONARY
Web dolutegravir (doe-loo-teg–ra-vir ) , Tivicay (trade name) Classification Therapeutic: antiretrovirals Pharmacologic: integrase strand transfer inhibitors Pregnancy Category: B …
From medical-dictionary.thefreedictionary.com


DOLUTEGRAVIR - USES, DMF, DOSSIER, MANUFACTURER, SUPPLIER, …
Web Dolutegravir is indicated for HIV-1 infection for adults and children and adolescents >=12 years of age and weighing >=40 kg. It is marketed as Tivicay as dolutegravir sodium. …
From pharmacompass.com


DOLUTEGRAVIR: MEDLINEPLUS DRUG INFORMATION
Web Dolutegravir comes as a tablet and as a tablet for suspension (a tablet to dissolve in liquid) to take by mouth. It is usually taken once or twice a day with or without food. Take …
From medlineplus.gov


2023-2031, RESEARCH ON THE DOLUTEGRAVIR AND ITS ... - MARKETWATCH
Web May 9, 2023 The Europe market for Dolutegravir and Its Combination Drug is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR of Percent …
From marketwatch.com


ORIGINAL ARTICLE RELATIVE BIOAVAILABILITY OF A PAEDIATRIC GRANULE ...
Web The dolutegravir granule was provided in unit-dose bottles containing 50 mg of dolutegravir in 10 g of granule. All formulations were administered in the fast- ing state. …
From journals.sagepub.com


Related Search